President and Chief Executive Officer Robert I. Blum of Cytokinetics Inc (NASDAQ:CYTK) disclosed a sale of company stock on April 1, 2026. According to a Form 4 filed with the Securities and Exchange Commission, Blum sold 7,500 shares of Cytokinetics common stock at $66.63 per share, resulting in total proceeds of $499,724.
The transaction took place while Cytokinetics shares were trading near a 52-week high of $70.98, after the stock appreciated roughly 76% over the past 12 months. The filing shows that, following the sale, Blum retains direct ownership of 422,830 shares of Cytokinetics common stock.
In addition to his direct holdings, Blum has indirect ownership stakes through family trusts. The filing reports 2,083 shares held through The Bridget Blum 2003 Irrevocable Trust and another 2,083 shares held through The Brittany Blum 2003 Irrevocable Trust.
Separately, third-party analysis noted that Cytokinetics presently appears overvalued relative to its Fair Value, and a comprehensive Pro Research Report covering CYTK and more than 1,400 U.S. equities is available for investors seeking further valuation context.
Analyst activity and trial milestones
Investor attention around Cytokinetics has been accompanied by multiple recent analyst actions tied to the company’s clinical and commercial progress. Several firms have reiterated or raised ratings and price targets as they weigh the implications of the U.S. approval of Myqorzo for obstructive hypertrophic cardiomyopathy and the upcoming Phase 3 ACACIA trial evaluating Myqorzo (aficamten) in non-obstructive hypertrophic cardiomyopathy.
- Evercore ISI reiterated an Outperform rating with a $80 price target and emphasized the potential impact of the forthcoming ACACIA Phase 3 trial for Myqorzo in non-obstructive HCM.
- Mizuho raised its price target to $100, citing an extension of the intellectual property projection for aficamten to 2041 and increasing its probability of success for the non-obstructive indication to 75%.
- JPMorgan adjusted its price target to $75 while maintaining an Overweight rating, noting favorable market conditions after Myqorzo’s approval for obstructive HCM.
- Stifel reiterated a Buy rating with a $98 price target and assigned a 70% probability of success for the ACACIA trial based on prior data.
- Leerink Partners reiterated an Outperform rating with an $84 price target and expressed confidence in the U.S. launch of Myqorzo and the anticipated ACACIA-HCM trial results.
What this filing shows
The Form 4 filing documents an insider sale by the company’s top executive but also confirms continued substantial direct ownership by Blum. The disclosed indirect holdings through two irrevocable trusts add to the picture of his family’s retained exposure to the equity. At the same time, public-facing analyst commentary and updated price targets highlight how near-term clinical milestones and intellectual property considerations are being priced by market participants and sell-side research teams.
Investor note - The filing and analyst updates provide specific data points for shareholders and market watchers to incorporate into their own valuation and risk assessments. The company’s trajectory in the near term will likely be influenced by ACACIA trial outcomes, execution of the U.S. launch for Myqorzo, and how the market reconciles current share price levels with formal Fair Value assessments.